白雲山:2024年第一季度報告
Baiyun Mountain (00874): Mingxing Pharmaceutical's dopamine hydrochloride injection obtained approval for drug supplementation
Baiyunshan (00874) announced that recently, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (hereinafter referred to as...
Baiyun Mountain (00874) plans to renew the employment of Daxin Certified Public Accountants
According to Zhitong Finance App, Baiyunshan (00874) announced that the company plans to renew Daxin Certified Public Accountants (Special General Partnership) as an accounting firm.
Baiyun Mountain (600332.SH): Branch drugs passed generic drug consistency evaluation
Gelonghui, April 22丨Baiyunshan (600332.SH) announced that the company's branch Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (“Baiyunshan Pharmaceutical General Factory”) received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. Cefixime tablets have passed the consistent evaluation of the quality and efficacy of generic drugs.
Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Stalled
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world, we'd like to see a company investing more capital into its business and ideally t
白雲山:2023年年報
Baiyun Mountain (600332.SH): Sildenafil citrate receives approval notice for application for marketing of chemical raw materials
Gelonghui, April 17, Baiyunshan (600332.SH) announced that the branch company Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Chemical Pharmaceutical Factory received a notice of approval for the marketing application of sildenafil citrate as a chemical ingredient approved and issued by the State Drug Administration on April 16, 2024. Sildenafil citrate is mainly used to treat erectile dysfunction.
Baiyunshan (00874.HK) plans to hold a board meeting on April 26 to approve quarterly results
Gelonghui, April 12, 丨 Baiyunshan (00874.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 26, 2024 (Friday) to review and approve the unaudited financial results of the company and its subsidiaries for the three months ended March 31, 2024 and handle other matters (if any).
BAIYUNSHAN PH: Date of Board Meeting
Improved Earnings Required Before Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Find Their Feet
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) price-to-earnings (or "P/E") ratio of 6.8x might make it look like a buy right now compared to the market in Hong Kong, where a
Hong Kong Stock Announces Nuggets | Xiaopeng Motor-W delivered a total of 9026 smart electric vehicles in March, up 99% month-on-month, up 29% year-on-year
Xiaopeng Automobile-W delivered a total of 9026 smart electric vehicles in March, up 99% year on month, up 29% year on year; Hisense Home Appliances released annual results, net profit of 2,837 billion yuan, up 97.73% year on year
Baiyun Mountain (00874.HK): 13 enterprises including the company and its subsidiaries have passed the high-tech enterprise certification
Gelonghui, April 2, Baiyunshan (00874.HK) announced that recently, 13 enterprises including the company and its subsidiaries Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. have passed the high-tech enterprise certification and received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Taxation Bureau of the State Administration of Taxation.
Baiyun Mountain (600332.SH): Approved as a high-tech enterprise
Gelonghui, April 1, Baiyunshan (600332.SH) announced that 13 enterprises including the company and its subsidiaries Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. have passed the high-tech enterprise certification and received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Taxation Bureau of the State Administration of Taxation.
Earnings Miss: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed EPS By 5.3% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) released its annual result to the market. The early response was not positive, with shares do
Baiyunshan Pharmaceutical's 2023 Profit Rises 2%
Guangzhou Baiyunshan Pharmaceutical Holdings' (SHA:600332, HKG:0874) attributable profit increased 2.25% to 4.06 billion yuan, or 2.495 yuan per share, in 2023, from 3.97 billion yuan, or 2.44 yuan pe
Changes in Hong Kong stocks | Baiyunshan (00874) fell more than 5%, net profit to mother fell 46.27% year-on-year in the fourth quarter of last year
The Zhitong Finance App learned that Baiyun Mountain (00874) fell by more than 5%. As of press release, it fell 4.84% to HK$20.65, with a turnover of HK$63.917 million. According to the news, Baiyunshan recently released its 2023 annual results. During the reporting period, the company achieved total operating revenue of 75.515 billion yuan, an increase of 6.68% over the previous year; net profit to mother was 4,056 billion yuan, an increase of 2.25% over the previous year. Compared with 27.6% in 2021 and 6.63% in 2022, Baiyun Mountain's net profit growth rate has been slowing for three consecutive years. Furthermore, based on single-quarter data, the total revenue for the fourth quarter was 173
Baiyunshan plans to distribute a cash dividend of 0.749 yuan per share
Baiyunshan (00874) announced the 2023 annual profit distribution plan and plans to distribute a cash dividend of RMB 0.749 (tax included) per share to all shareholders.
Baiyunshan appoints Liu Fei as the company's financial director
Baiyunshan (00874) announced that on March 15, 2024, based on the nomination of the company's general manager, after approval by the company's board of directors nomination and qualification review by the remuneration committee, and review and approval by the company board review committee, the board of directors of the company agreed to appoint Ms. Liu Fei as the company's financial director for a term of office beginning on the date of review and approval by the board of directors until the end of the term of the 9th board of directors.
Baiyun Mountain (00874) plans to distribute a discovery dividend of 0.749 yuan per share
Baiyunshan (00874) announced the 2023 annual profit distribution plan to distribute cash dividends to all shareholders per share...
Baiyunshan (00874) appoints Liu Fei as the company's financial director
Baiyun Mountain (00874) announced that on March 15, 2024, according to the nomination of the company's general manager...
No Data